araag2/HINT huggingface dataset:
Clinical trial NCT00303563 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: p38 inhibitor (4), p38 inhibitor (4), p38 inhibitor (4), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >18 years of age, with active RA;

          -  receiving treatment for RA on an outpatient basis;

          -  females of child-bearing potential, or nonsterilized males with partners of
             child-bearing potential, must use reliable contraception during, and for 4 weeks
             after, the study.

        Exclusion Criteria:

          -  major surgery within 8 weeks prior to screening;

          -  rheumatic autoimmune disease or inflammatory joint disease other than RA;

          -  treatment with methotrexate within 8 weeks of baseline;

          -  concurrent use of DMARDs, including anti-TNF or other biologic therapy for RA.
Clinical trial NCT01417663 (phase 2/phase 3, status: completed)
Conditions: cardiovascular disease, aging, endothelial dysfunction, physical activity
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, H18.513, H18.511, H18.512, H18.519
Drugs: alt-711
SMILES: CC1=C(C)[N+](CC(=O)C2=CC=CC=C2)=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy sedentary elderly

          -  Age 65 yrs and older

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Cerebrovascular disease

          -  Changes on ECG indicating cardiomyopathy or ischemia

          -  No cardiovascular medication

          -  Diabetes Mellitus

          -  Hypercholesterolemia

          -  BMI > 33 kg/m2

          -  Intensive exercise > 1 hour a week
Clinical trial NCT00451152 (phase 2, status: completed)
Conditions: open-angle glaucoma
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: anecortave acetate sterile suspension, 30 mg/ml
SMILES: [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of open-angle glaucoma;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pseudoexfoliation;

          -  Pigment dispersion component;

          -  Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00755118 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: oxaliplatin, 5-fluorouracil, leucovorin, bevacizumab, irinotecan, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic colorectal cancer

          -  Measurable or evaluable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST)

          -  ECOG performance status ≤ 2

          -  Age 18 - 72 years

          -  Patients who progress after 1st line therapy with FOLFOX/AVASTIN

          -  Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit,
             ALP ≤ 2.5 upper normal limit),renal (Creatinine ≤ 1.5 upper normal limit) and bone
             marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function

          -  Patients must be able to understand the nature of this study

          -  Written informed consent

          -  Previous treatments with all effective drugs for metastatic colorectal cancer (CPT-11,
             LOHP, 5-FU/XELODA, Erbitux, Avastin)

        Exclusion Criteria:

          -  History of serious cardiac disease (unstable angina, congestive heart
             failure,uncontrolled cardiac arrhythmias)

          -  History of myocardial infarction or stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess
             within 28 days prior to Day 0

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
             prior to Day 1

          -  Presence of central nervous system or brain metastases

          -  Evidence of bleeding diathesis or coagulopathy

          -  Blood pressure > 150/100 mmHg

          -  Pregnant or lactating woman

          -  Life expectancy < 3 months

          -  Previous radiotherapy within the last 4 weeks or > 25% of bone marrow

          -  Metastatic infiltration of the liver >50%

          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or
             total colectomy

          -  Active infection requiring antibiotics on Day 1

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer

          -  Psychiatric illness or social situation that would preclude study compliance
Clinical trial NCT01303744 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: chf 5074 1x, chf 5074 2x, chf 5074 3x, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.

          -  Mini-Mental State Examination score higher than 24 at screening.

          -  MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR)
             and T2*-weighted gradient-recalled-echo (GRE) sequences.

        Exclusion Criteria:

          -  Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA
             criteria.

          -  Any medical condition that could explain the patients cognitive deficits.

          -  CT or MRI brain imaging results obtained within 12 months prior to baseline showing
             evidence of infection, infarction, or focal lesions of clinical significance

          -  MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with
             diameter ≤ 10 mm).

          -  Geriatric Depression Scale (30-point scale) score > 9 at screening.

          -  History of stroke.

          -  Modified Hachinski ischemic scale score > 4 at screening.

          -  Women of childbearing potential.

          -  Vitamin B12 or folate deficiency.

          -  Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar
             disorders) within 3 years of screening.

          -  Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year
             and/or chronic inflammatory bowel disease.

          -  Concomitant use of donepezil at doses > 5 mg/day or other cholinesterase inhibitors
             (rivastigmine or galantamine) at any dose.

          -  Concomitant use of memantine at dose > 20 mg/day.

          -  Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).
Clinical trial NCT00484601 (phase 2, status: terminated)
Conditions: refractory nasopharyngeal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: ifosfamide, doxorubicin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of NPC

          -  Age > 18 years old

          -  Measurable metastatic or recurrent disease (s)

          -  Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed
             or became refractory before entry.

          -  ECOG PS 0, 1 or 2

          -  WBC > 3,500/uL and ANC > 1,500/uL Platelet > 100,000/uL Creatinine - within normal
             limits SGOT < 3 X UNL Bilirubin < 2.0 mg/dL

          -  Ejection fraction > 45% and no history of myocardial infarction or congestive heart
             failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle
             tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with
             hemodynamic compromising status.

          -  Random blood glucose level < 250 mg

          -  Signed informed consent

        Exclusion Criteria:

          -  Received more than one prior chemotherapy for metastatic or recurrent disease

          -  Ejection fraction < 45%

          -  WBC < 3,500/UL or ANC < 1,500/UL or P/t < 100,000/UL or SCOT> 3 x UNL or Bilirubin >
             2.0 mg/dL or Creatinine > UNL

          -  ECOG PS > 3

          -  Hx of myocardial infarction within last 6 months

          -  Random blood glucose level less than or equal 250 mg
Clinical trial NCT00528450 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: arsenic trioxide, idarubicin, tretinoin
SMILES: O=[As]O[As]=O, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Morphologic diagnosis of acute promyelocytic leukemia (APL), confirmed by one of the
             following:

               -  Demonstration of t(15;17) using conventional cytogenetics or fluorescence in situ
                  hybridization (FISH)

               -  Positive PML-RARα transcript by reverse transcriptase-polymerase chain reaction
                  (RT-PCR) assay

          -  Patients with CNS involvement by APL are eligible

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Creatinine ≤ 2.0 mg/dL or creatinine clearance > 60 mL/min

          -  Bilirubin < 2.0 mg/dL (unless attributed to Gilbert disease)

          -  Alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 ULN

          -  LVEF ≥ 50% on echocardiogram or MUGA scan

          -  QTc ≤ 500 msec on baseline ECG

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 4 months after the
             completion of study treatment

          -  No active serious infections not controlled by antibiotics

          -  No other concurrent active malignancy requiring immediate therapy

          -  No clinically significant cardiac disease (New York Heart Association class III or IV
             heart disease), including chronic arrhythmias

          -  No pulmonary disease

          -  No other serious or life-threatening condition deemed unacceptable by the principal
             investigator

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment for APL
Clinical trial NCT01060878 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: pym50028, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  confirmed diagnosis of early-stage idiopathic PD within the 2 years prior to screening

          -  subjects who are not currently receiving any PD treatment

        Exclusion Criteria:

          -  female of child-bearing potential

          -  history of neurosurgical procedures for PD

          -  history of severe psychiatric illness
Clinical trial NCT01148173 (phase 2, status: unknown status)
Conditions: lymphoma, non-hodgkin
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: combined systemic and intrathecal chemotherapy followed by hd-asct
SMILES: ClCCNC(=O)N(CCCl)N=O
Eligibility criteria:

        Inclusion Criteria:

          -  highly-malignant non-Hodgkins-Lymphoma, mantle-cell lymphoma or follicular lymphoma 3°

          -  CNS relapse (meningeal or/and intraparenchymal) with or without systemic lymphoma
             manifestations

          -  ECOG performance score ≤2

          -  no active infection

          -  negative HIV-serology

          -  adequate renal function (creatinine clearance > 50 ml/min)

          -  adequate bone marrow function (granulocytes >1500/μl, platelets > 80000/μl)

          -  normal bilirubin, AST < 3 x UNL

          -  negative pregnancy test

        Exclusion Criteria:

          -  newly diagnosed NHL with primary CNS involvement

          -  indolent NHL, lymphoblastic NHL or Burkitt lymphoma

          -  preceding CNS irradiation

          -  pretreatment of CNS relapse other than corticosteroids

          -  immunosuppression, concomitant immunosuppressive therapy, status after organ
             transplantation or allogenous stem cell transplantation

          -  second cancer other than basalioma or cervical carcinoma in situ within the last 5
             years

          -  unfit to receive an intensive chemotherapy

          -  pregnancy or breastfeeding

          -  known intolerance to MTX, ifosfamide, Depocyte, cytarabine, thiotepa, carmustine or
             etoposide
Clinical trial NCT00377520 (phase 2, status: completed)
Conditions: neoplasms, neoplasms by site, urogenital neoplasms, genital neoplasms, female, uterine neoplasms, endometrial neoplasms, cancer of endometrium, endometrial cancer, cancer of the endometrium, endometrium cancer, neoplasms, endometrial
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.9, D28.9, C57.7, D28.7, C57.8, D39.9, D39.8, C57.4, D28.2, N85.00, N85.01, N85.02, N99.85, N85.00, N85.01, N85.02, N99.85
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have recurrent or persistent endometrial adenocarcinoma, which is
             refractory to curative therapy or established treatments.

          -  Patients must have measurable disease.

          -  Patients must have had one prior chemotherapeutic regimen for management of
             endometrial carcinoma.

          -  Patients must have signed an approved informed consent.

          -  Patients of childbearing potential must have a negative serum pregnancy test prior to
             the study entry and be practicing an effective form of contraception during the study
             and for at least 3 months following the last dose of Pemetrexed.

          -  Patients must discontinue nonsteroidal anti-inflammatory (NSAIDs) medications 2-5 days
             prior to and for 1-2 days after receiving Pemetrexed, depending on the half-life of
             the NSAIDs treatment.

          -  Patients must agree to this schedule in conjunction with every dose of Pemetrexed.

          -  Patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting
             7 days prior to the first treatment with Pemetrexed.

          -  Patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after
             the last dose of Pemetrexed.

          -  Patients must receive 4 mg Dexamethasone by mouth twice daily, 1 day prior to the
             dose, the day of and the day after every dose of Pemetrexed.

          -  Patients must receive a 1000 mcg vitamin B12 injection 7 days prior to receiving the
             first treatment with Pemetrexed.

          -  Patients must agree to receive 1000 mcg vitamin B12 injection every 9 weeks until 3
             weeks after the last dose of Pemetrexed.

        Exclusion Criteria:

          -  Patients who have had prior therapy with Pemetrexed

          -  Patients who have received radiation to more than 25% of marrow bearing areas
Clinical trial NCT00192114 (phase 2, status: completed)
Conditions: colonic neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: enzastaurin hcl
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosed with colorectal cancer that is advanced or metastatic (has spread to other
             parts of the body); able to visit the doctor's office every 28 days for at least 6
             months; able to swallow tablets

        Exclusion Criteria:

          -  women cannot be pregnant or breastfeeding; no history of significant heart disease or
             any other significant medical problems as determined by the participant's physician
Clinical trial NCT01641692 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: gsk573719 active treatment or placebo, salbutamol/albuterol
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Outpatient (sub-group will have 3 overnight stays at clinic)

          -  Diagnosis of asthma (NIH 2007) for at least 6 months

          -  Male or Eligible female (females of child-bearing potential must use acceptable method
             of birth control)

          -  A best AM pre-bronchodilator FEV1 of 60% to 85% of predicted normal value at Screening

          -  Reversibility of disease demonstrated by at least 12% and 200mL increase in FEV1 .

          -  Subjects must have been prescribed a non-corticosteroid controller at least 3 months
             preceding Visit 1, and/or a short-acting beta 2 agonist, without the use of inhaled
             corticosteroids in the 4 weeks prior to Visit 1

          -  Subjects must be able to replace their current short-acting Beta-2-agonist with
             albuterol/salbutamol aerosol inhaler for the duration of the study

          -  Subjects must be judged capable of withholding albuterol/salbutamol for at least 4
             hours prior to study visits

        Exclusion Criteria:

          -  History of life threatening asthma

          -  Severe asthma exacerbation

          -  Respiratory infection within expected to affect subject's ability to participate

          -  Concurrent respiratory disease

          -  Current smoker or smoking history of 10 pack years or more

          -  Diseases preventing use of anticholinergics

          -  Other clinically significant, uncontrolled condition or disease which would pose a
             safety risk to the patient, or confound interpretation of study results

          -  Drug allergy to any Beta-2-agonist, sympathomimetic drug, intranasal, inhaled or
             systemic corticosteroid therapy

          -  Known or suspected sensitivity to the constituents of the Novel DPI (ie lactose)

          -  History of severe milk protein allergy

          -  Administration of prescription or over-the-counter medication that would significantly
             affect the course of asthma, or interact with the study drug

          -  Any infirmity, disability or disease of a child or family member likely to impair
             compliance

          -  Alcohol or substance abuse history

          -  Viral hepatitis B surface antigen or Hepatitis C antibody

          -  Known HIV-positive history.

          -  Affiliation with investigator or site staff
Clinical trial NCT01591044 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: placebo, r940343 1mg, r940343 2mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical history of asthma

          -  Ability to perform spirometry

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease or bronchiectasis

          -  Upper or lower respiratory infection
Clinical trial NCT00093002 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women defined as women who have stopped having menstrual periods

          -  Written informed consent to participate in the trial

          -  Biopsy confirmation of invasive breast cancer

          -  Evidence of hormone sensitivity

          -  Willingness to undergo biopsies

        Exclusion Criteria:

          -  Any previous treatment for breast cancer

          -  Unwillingness to stop taking any drug known to affect sex hormonal status or a patient
             in which it would be inappropriate to stop.

          -  Any severe concurrent condition that would preclude surgery or that would jeopardize
             compliance with the study, e.g., uncontrolled cardiac disease or uncontrolled diabetes
             mellitus

          -  The presence of more than one primary tumor

          -  History of hypersensitivity to castor oil

          -  History of known bleeding disorders
Clinical trial NCT00486291 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vi-0521, placebo
SMILES: CC(C)(N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Type 2 Diabetes

          -  BMI 27-42

          -  Specified diet/exercise and/or diabetes medications

        Exclusion Criteria:

          -  BP > 150/95

          -  Stroke/MI/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic, or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  History of glaucoma

          -  Pregnancy or breastfeeding

          -  Alcohol abuse

          -  Eating disorder

          -  Excluded medications
Clinical trial NCT01048333 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: formoterol, salmeterol, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A clinical diagnosis of COPD according to GOLD guidelines, and current COPD symptoms

          -  A current or previous smoking history equivalent to 10 or more packs per year (1 pack
             year = 20 cigarettes smoked per day for one year).

          -  Documented use of a short-acting inhaled bronchodilator (β2-agonist or
             anticholinergics) as reliever medication.

        Exclusion Criteria:

          -  A history and/or current diagnosis of asthma.

          -  Patients who have experienced COPD exacerbation requiring hospitalisation and/or a
             course of antibiotics and/or a course of systemic steroid within 30 days (from end of
             exacerbation treatment) prior to Visit 1 and/or during the run-in period.

          -  A history and/or current diagnosis of atopic diseases such as allergic rhinitis or
             eczema before the age of 40.